Antibody Discovery Services
Accelerate antibody discovery with Fusion Antibodies’ integrated, multi-platform CRO workflow designed to deliver high-quality monoclonal antibodies, recombinant antibodies, and therapeutic leads for preclinical and translational drug development.
Antibody Discovery Services
Accelerate antibody discovery with Fusion Antibodies’ integrated, multi-platform CRO workflow designed to deliver high-quality monoclonal antibodies, recombinant antibodies, and therapeutic leads for preclinical and translational drug development.
Fusion Antibodies is a specialist contract research organisation (CRO) supporting antibody discovery and engineering services from antigen design through to validated lead selection. Our integrated platforms utilize hybridoma technology, rabbit monoclonal discovery, phage display antibody discovery, mammalian display, and AI-assisted antibody discovery to maximise epitope coverage, functional diversity, and developability of candidate antibodies.
We support biotech and pharmaceutical teams seeking an end-to-end antibody development partner for biologics discovery, lead optimisation, and preclinical drug discovery programmes.
What is antibody discovery?
Antibody discovery is the process of identifying and isolating antibodies that bind specifically to a biological target (antigen), typically for therapeutic, diagnostic, or research applications.
In therapeutic antibody discovery, the goal is to generate antibodies that are not only high-affinity binders but also:
- Functionally active against the target biology
- Structurally stable and manufacturable
- Suitable for downstream antibody engineering and development
- Compatible with humanisation and affinity maturation strategies
Modern antibody discovery integrates multiple technologies including antibody library design, antibody library screening, display systems, and immunisation-based methods to maximise success rates.
Common challenges in antibody discovery programmes
Antibody discovery programmes often fail or slow due to predictable technical bottlenecks in early biologics discovery:
- Suboptimal antigen design leading to weak or irrelevant immune responses
- Platform mismatch between discovery method and target biology (e.g. membrane proteins vs soluble antigens)
- Limited epitope diversity caused by immunodominance in animal systems
- Downstream engineering constraints such as humanization, affinity maturation, or antibody optimisation challenges
- Developability risks including aggregation, poor expression, or instability
- Unpredictable timelines from iterative screening or low-yield campaigns
These challenges directly impact progression into lead optimisation, antibody characterisation, and preclinical development.
Fusion Antibodies mitigate these risks through early-stage scientific design, differentiated discovery workflows, and integrated developability assessment.
Fusion’s antibody discovery workflow
Our antibody discovery process is designed to connect upstream biological insight with downstream therapeutic development.
Target analysis
We evaluate biological context, disease relevance, and therapeutic modality to define discovery strategy and epitope requirements.
Antigen design
We engineer optimised antigen constructs to improve immune response, display selection, and epitope presentation.
Platform selection
We select the most appropriate discovery route based on target class, risk profile, and downstream therapeutic format:
- Hybridoma antibody discovery
- Rabbit monoclonal antibody discovery
- Phage display antibody discovery
- Mammalian display service (OptiMAL®)
- AI antibody discovery (AI/ML-ab™)
Screening and validation
We identify and validate antigen-specific binders using antibody library screening, functional assays, and binding characterisation.
Candidate selection
We prioritise lead antibodies based on affinity, specificity, expression, stability, and early developability assessment.
This structured workflow ensures alignment with downstream steps including antibody humanization, affinity maturation, and recombinant antibody expression.
Fusion’s five antibody discovery platforms
Fusion Antibodies provide multiple antibody discovery platforms for broader epitope coverage, reducing risk, and greater flexibility than having to rely on a single method.
Our capacity to integrate immune-derived, display-based, and computational methods will maximise hit quality and therapeutic relevance. We improves the probability of identifying therapeutic antibodies with optimal biological and developability profiles.
Platform comparison overview
| Description | Key advantage | |
|---|---|---|
| Mouse Hybridoma (hybridoma antibody discovery) | Classic immunisation-based monoclonal antibody generation followed by screening | Robust, widely validated, cost-effective |
| Rabbit B-cell cloning (rabbit discovery) | Rabbit immunisation followed by B-cell screening for monoclonal antibodies | Higher affinity, broader epitope recognition |
| Phage display (OptiPhage®) | Antibody library screening using phage-displayed recombinant antibodies | Fully human antibody fragments, well-suited for producing modular components for bispecifics. |
| Mammalian display (OptiMAL®) | Cell-surface display of full-length human IgG | Native-format antibodies without humanisation and incorporating developability screening |
| AI/ML-guided discovery (AI/ML-ab™) | In silico antibody library design and mammalian display screening with wet-lab validation | Accelerates hit identification and epitope prioritisation |
How antibody engineering connects to discovery
Antibody discovery is tightly linked to downstream antibody engineering and optimisation.
Once lead antibodies are identified, they typically progress into:
- Antibody humanization (if non-human systems are used)
- Affinity maturation to improve binding strength
- Antibody optimisation for stability, expression, and specificity
- Antibody sequencing for recombinant production
- Antibody expression and production for preclinical studies
This integrated approach ensures a smooth transition from discovery to biologics development and preclinical drug discovery.
Key benefits of Fusion’s discovery strategy
Our integrated approach to antibody discovery delivers:
- Broader epitope coverage across complex biological targets
- Higher-quality hits through different discovery workflows
- Reduced risk for difficult or conserved antigens
- Improved developability through early screening integration
- Faster progression to lead optimisation and candidate selection
- Flexible formats including IgG, bispecific antibodies, CAR-related formats, and multispecifics
In summary, Fusion’s platform strategy transforms antibody discovery from a trial-and-error process into a strategy-driven biologics discovery engine built to maximize success.
Why partner with Fusion Antibodies?
Fusion Antibodies operates as a specialist CRO focused on antibody discovery and engineering services for biotech and pharmaceutical partners.
We provide:
- Over 20 years of antibody discovery expertise
- Integrated workflows from antigen design to lead selection
- Expertise across monoclonal antibodies, recombinant antibodies, and therapeutic antibody discovery
- Flexible platform selection tailored to each project’s biological and development constraints
- Experience supporting diverse preclinical drug discovery programmes
We function as a collaborative contract research organisation (CRO) embedded in your discovery strategy.
Start your antibody discovery programme
Work with Fusion Antibodies to accelerate your therapeutic antibody pipeline with scientifically rigorous, multi-platform discovery strategies.
Contact us to discuss your antibody discovery programme.
Tell us what you’re working on.
Share the useful starting details and your enquiry will be sent securely to Fusion’s scientific team.